Volume 71, Issue 2_suppl
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645


Each year, up to three million deaths due to malaria and close to five billion episodes of clinical illness possibly meriting antimalarial therapy occur throughout the world, with Africa having more than 90% of this burden. Almost 3% of disability adjusted life years are due to malaria mortality globally, 10% in Africa. New information is presented in this supplement on malaria-related perinatal mortality, occurrence of human immunodeficiency virus in pregnancy, undernutrition, and neurologic, cognitive, and developmental sequelae. The entomologic determinants of transmission and uses of modeling for program planning and disease prediction and prevention are discussed. New data are presented from the Democratic Republic of the Congo, Tanzania, Ethiopia, and Zimbabwe on the increasing urban malaria problem and on epidemic malaria. Between 6% and 28% of the malaria burden may occur in cities, which comprise less than 2% of the African surface. Macroeconomic projections show that the costs are far greater than the costs of individual cases, with a substantial deleterious impact of malaria on schooling of patients, external investments into endemic countries, and tourism. Poor populations are at greatest risk; 58% of the cases occur in the poorest 20% of the world’s population and these patients receive the worst care and have catastrophic economic consequences from their illness. This social vulnerability requires better understanding for improving deployment, access, quality, and use of effective interventions. Studies from Ghana and elsewhere indicate that for every patient with febrile illness assumed to be malaria seen in health facilities, 4–5 episodes occur in the community. Effective actions for malaria control mandate rational public policies; market forces, which often drive sales and use of drugs and other interventions, are unlikely to guarantee their use. Artemisinin-based combination therapy (ACT) for malaria is rapidly gaining acceptance as an effective approach for countering the spread and intensity of resistance to chloroquine, sulfadoxine/pyrimethamine, and other antimalarial drugs. Although costly, ACT ($1.20–2.50 per adult treatment) becomes more cost-effective as resistance to alternative drugs increases; early use of ACT may delay development of resistance to these drugs and prevent the medical toll associated with use of ineffective drugs.

The burden of malaria in one district in Tanzania has not decreased since the primary health care approach replaced the vertical malaria control efforts of the 1960s. Despite decentralization, this situation resulted, in part, from weak district management capacity, poor coordination, inadequate monitoring, and lack of training of key staff. Experience in the Solomon Islands showed that spraying with DDT, use of insecticide-treated bed nets (ITNs), and health education were all associated with disease reduction. The use of nets permitted a reduction in DDT spraying, but could not replace it without an increased malaria incidence. Baseline data and reliable monitoring of key outcome indicators are needed to measure whether the ambitious goals for the control of malaria and other diseases has occurred. Such systems are being used for evidence-based decision making in Tanzania and several other countries. Baseline cluster sampling surveys in several countries across Africa indicate that only 53% of the children with febrile illness in malarious areas are being treated; chloroquine (CQ) is used 84% of the time, even where the drug may be ineffective. Insecticide-treated bed nets were used only 2% of the time by children less than five years of age. Progress in malaria vaccine research has been substantial over the past five years; 35 candidate malaria vaccines are in development, many of which are in clinical trials. Development of new vaccines and drugs has been the result of increased investments and formation of public-private partnerships. Before malaria vaccine becomes deployed, consideration must be given to disease burden, cost-effectiveness, financing, delivery systems, and approval by regulatory agencies. Key to evaluation of vaccine effectiveness will be collection and prompt analysis of epidemiologic information. Training of persons in every aspect of malaria research and control is essential for programs to succeed. The Multilateral Initiative on Malaria (MIM) is actively promoting research capacity strengthening and has established networks of institutions and scientists throughout the African continent, most of whom are now linked by modern information-sharing networks. Evidence over the past century is that successful control malaria programs have been linked to strong research activities. To ensure effective coordination and cooperation between the growing number of research and control coalitions forming in support of malaria activities, an umbrella group is needed. With continued support for scientists and control workers globally, particularly in low-income malarious countries, the long-deferred dream of malaria elimination can become a reality.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Yamey G, 2000. African heads of state promise action against malaria. BMJ 320: 1228. [Google Scholar]
  2. Breman JG, ed, 2001. The intolerable burden of malaria: a new look at the numbers. Am J Trop Med Hyg 64 (Suppl 1–2): 1–106. [Google Scholar]
  3. Jamison DT, 2002. Cost-effectiveness analysis: concept and applications. Oxford Textbook of Public Health Volume 4, Detels R, McEwen J, Beaglehole R, Tanaka H, eds. Oxford, United Kingdom: Oxford University Press, 903–919.
  4. Breman JG, 2001. The ears of the hippopotamus: manifestations, determinants and estimates of the malaria burden. Am J Trop Med Hyg 64 (Suppl 1–2): 1–11. [Google Scholar]
  5. Snow RW, Craig MH, Newton CRJC, Steketee RW, 2003. The Public Health Burden of Plasmodium falciparum Malaria in Africa: Deriving the Numbers. Working Paper No. 11. Disease Control Priorities Project, Bethesda, MD: Fogarty International Center, National Institutes of Health, August 2003.
  6. Murphy SC, Breman JG, 2001. Gaps in the childhood malaria burden in Africa: cerebral malaria, neurologic sequelae, anemia, respiratory distress, hypoglycemia and complications of pregnancy. Am J Trop Med Hyg 64 (Suppl 1–2): 57–67. [Google Scholar]
  7. World Health Organization, 2002. Annex Table 3: Burden of disease in DALYs by cause, sex and mortality stratum in WHO regions, estimates for 2001. World Health Report, 2002: Reducing Risks, Promoting Healthy Life. Geneva: World Health Organization, 192–197.
  8. Hay SI, Guerra CA, Tatem AJ, Noor AM, Snow RW, 2004. The global distribution and population at risk of malaria: past, present and future. Lancet Infect Dis 4: 327–336. [Google Scholar]
  9. Marsh K, Foster P, Wariuru C, Mwangi I, Winstanley M, Marsh V, Newton C, Pasvol G, Snow R, 1995. Indicators of life-threatening malaria in African children. N Engl J Med. 332: 1399–1404. [Google Scholar]
  10. Samba E, 2004. Bringing research, training and service delivery together to reduce the malaria burden in Africa. Am J Trop Med Hyg 71 (Suppl 2): iii–iv. [Google Scholar]
  11. Ntoumi F, Djimdé A, Mbacham W, Egwang T, 2004. The importance and future of malaria research in Africa. Am J Trop Med Hyg 71 (Suppl 2): iv–vii. [Google Scholar]
  12. Snow RW, Korenromp E, Drakely C, Gouws E, 2004. Pediatric mortality in Africa: Plasmodium falciparum malaria as a cause or risk? Am J Trop Med Hyg 71 (Suppl 2): 16–24. [Google Scholar]
  13. Lackritz EM, Campbell CC, Ruebush TK II, Hightower AW, Wakube W, Steketee RW, Were JB, 1992. Effect of blood transfusions on survival among children in a Kenyan hospital. Lancet 340: 524–528. [Google Scholar]
  14. Crawley J, 2004. Burden of clinical management and anemia in African children. Am J Trop Med Hyg 71 (Suppl 2): 25–34. [Google Scholar]
  15. van Geertruyden JP, Thomas F, Erhart A, D’Alessandro U, 2004. Malaria as an independent risk factor for perinatal mortality and/or stillbirths: a review and meta-analysis. Am J Trop Med Hyg 71 (Suppl 2): 35–40. [Google Scholar]
  16. ter Kuile F, Parise M, Verhoef F, Udhayakumar V, Newman RD, van Eijk AM, Rogerson SJ, Steketee RW, 2004. The burden of co-infection with human immunodeficiency virus type 1 and malaria in pregnant women in sub-Saharan Africa. Am J Trop Med Hyg 71 (Suppl 2): 41–54. [Google Scholar]
  17. Caulfield L, Richard SA, Black R, 2004. Undernutrition as an underlying cause of malaria morbidity and mortality. Am J Trop Med Hyg 71 (Suppl 2): 55–63. [Google Scholar]
  18. Mung’ala-Odera V, Snow RW, Newton C, 2004. The burden of the neurocognitive impairment associated with Plasmodium falciparum malaria in sub-Saharan Africa. Am J Trop Med Hyg 71 (Suppl 2): 64–70. [Google Scholar]
  19. Holding P, Kitsao-Wekulo PK, 2004. New perspectives on the causes and potential costs of malaria: The growth and development of children: What should we be measuring and how should we be measuring it? Am J Trop Med Hyg 71 (Suppl 2): 71–79. [Google Scholar]
  20. Smith T, Killeen G, Lengeler C, Tanner M, 2004. Relationship between the outcome of Plasmodium falciparum infection and the intensity of transmission in Africa. Am J Trop Med Hyg 71 (Suppl 2): 80–86. [Google Scholar]
  21. Killeen G, Seyoum A, Knols B, 2004. Rationalizing historical successes of malaria control in Africa in terms of mosquito resource availability management. Am J Trop Med Hyg 71 (Suppl 2): 87–93. [Google Scholar]
  22. McKenzie FE, Samba E, 2004. The role of mathematical modeling in evidence-based malaria control. Am J Trop Med Hyg 71 (Suppl 2): 94–96. [Google Scholar]
  23. Richards FO Jr, Boatin B, Sauerbrey M, Seketeli A, 2001. Control of onochocerciasis today: status and challenges. Trends Parasitol 17: 558–563. [Google Scholar]
  24. Molineaux L, Gramiccia G, 1980. The Garki Project; Research on the Epidemiology and Control of Malaria in the Sudan Savanna of West Africa. Geneva, World Health Organization.
  25. MacDonald G, 1957. The Epidemiology and Control of Malaria. Oxford, United Kingdom: Oxford University Press.
  26. Kazadi W, Sexton JD, Bigonsa M, W’Okanga B, Way M, 2004. Malaria in primary school children and infants in Kinshasa, Democratic Republic of the Congo. Am J Trop Med Hyg 71 (Suppl 2): 97–102. [Google Scholar]
  27. Caldas de Castro M, Yamagat Y, Mtasiwa D, Tanner M, Utzinger J, Keiser J, Singer BH, 2004. Integrated urban malaria control: a case study in Dar es Salaam, Tanzania. Am J Trop Med Hyg 71 (Suppl 2): 103–117. [Google Scholar]
  28. Keiser J, Utzinger J, Caldas de Castro M, Smith TA, Tanner M, Singer BH, 2004. Urbanization in sub-Saharan Africa and malaria control. Am J Trop Med Hyg 71 (Suppl 2): 118–127. [Google Scholar]
  29. Snow RW, Craig M, Deichmann U, Marsh K, 1999. Estimating mortality, morbidity, and disability due to malaria among Africa’s non-pregnant population. Bull World Health Org 77: 624–640. [Google Scholar]
  30. Kiszewski A, Teklehaimanot A, 2004. A review of the clinical and epidemiological burdens of epidemic malaria. Am J Trop Med Hyg 71 (Suppl 2): 128–135. [Google Scholar]
  31. Craig MH, Snow RW, LeSuer D, 1995. A climate-based distribution model of malaria transmission in sub-Saharan Africa. Parasitol Today 15: 105–111. [Google Scholar]
  32. Worrall E, Rietveld A, Delacollette C, 2004. The burden of malaria epidemics and cost-effectiveness of interventions in epidemic situations in Africa. Am J Trop Med Hyg 71 (Suppl 2): 136–140. [Google Scholar]
  33. Ruger JP, Jamison DT, Bloom DE, 2001. Health and the economy. Merson MH, Block RE, Mills A, eds. International Public Health. Sudbury, MA: Jones and Bartlett, 619.
  34. Gallup JL, Sachs JD, 2001. The economic burden of malaria. Am J Trop Med Hug 64 (Suppl 1–2): 85–96. [Google Scholar]
  35. The Abuja Declaration and the Plan of Action, April 25, 2000.(http://mosquito.who.int/docs/abuja_declaration.pdf).
  36. Russell S, 2004. The economic burden of illness for households in developing countries: catastrophic or manageable? A review of studies focusing on malaria, tuberculosis, and human immuno-deficiency virus/acquired immunodeficiency syndrome. Am J Trop Med Hyg 71 (Suppl 2): 147–155. [Google Scholar]
  37. Malaney P, Spielman A, Sachs J, 2004. The malaria gap. Am J Trop Med Hyg 71 (Suppl 2): 141–146. [Google Scholar]
  38. Jones C, Williams H, 2004. The social burden of malaria: what are we measuring? Am J Trop Med Hyg 71 (Suppl 2): 156–161. [Google Scholar]
  39. Agyepong I, Kengeya-Kayondo J, 2004. Providing practical estimates of the malaria burden for health planners in resource poor communities. Am J Trop Med Hyg 71 (Suppl 2): 162–167. [Google Scholar]
  40. Hanson K, 2004. Malaria control interventions: who should pay? Am J Trop Med Hyg 71 (Suppl 2): 168–173. [Google Scholar]
  41. Barat L, Palmer N, Basu S, 2004. Do malaria control interventions reach the poor? A view through the equity lens. Am J Trop Med Hyg 71 (Suppl 2): 174–178. [Google Scholar]
  42. Yeung S, Pongtavornpinyo W, Hastings IM, Mills AJ, White NJ, 2004. Antimalarial drug resistance, artemisinin-based combination therapy, and the contribution of modeling to elucidating policy choices. Am J Trop Med Hyg 71 (Suppl 2): 179–186. [Google Scholar]
  43. Trape JF, 2001. The public health impact of chloroquine resistance in Africa. Am J Trop Med Hyg 64: 12–17. [Google Scholar]
  44. Kolaczinski J, Mohammed N, Ali I, Ali M, Khan N, Ezard N, Rowland N, 2004. Comparison of the optimal rapid antigen test with field microsopy detection of Plasmodium vivax and P. falciparum: considerations for the application of the rapid test in Afghanistan. Ann Trop Med Parasitol 98: 15–20. [Google Scholar]
  45. White N, 1999. Antimalarial drug resistance and combination chemotherapy. Philos Trans R Soc Lond B Biol Sci 354: 739–749. [Google Scholar]
  46. Laxminarayan R, 2004. Act now or later? Economics of malaria resistance. Am J Trop Med Hyg 71 (Suppl 2): 187–195. [Google Scholar]
  47. Coleman P, Morel C, Shillcutt S, Goodman C, Mills A, 2004. A threshold analysis of the cost-effectiveness of artemisin-based combination therapies in sub-Saharan Africa. Am J Trop Med Hyg 71 (Suppl 2): 196–204. [Google Scholar]
  48. Shepard DS, Ettling MB, Brinkmann U, Sauerborn R, 1991. The economic cost of malaria in Africa. Trop Med Parasitol 42: 199–203. [Google Scholar]
  49. Snow RW, Eckert E, Teklehaimanot A, 2003. Estimating the needs for artesunate based combination therapy for malaria case management in Africa. Trends Parasitol 19: 363–369. [Google Scholar]
  50. Alilio M, Kitua A, Njunwa K, Medina M, Ronn AM, Mhina J, Msuya F, Mahundi J, Depinay JM, Whyte S, Krasnik A, Bygbjerg IC, 2004. Malaria control at the district level in Africa: a case of Muheza district in northeastern Tanzania. Am J Trop Med Hyg 71 (Suppl 2): 205–213. [Google Scholar]
  51. Over M, Bakote’e B, Vélayudhan R, Wilikai P, Graves P, 2004. Impregnated nets cannot fully substitute for DDT: field effectiveness of malaria prevention in Solomon Islands. Am J Trop Med Hyg 71 (Suppl 2): 214–223. [Google Scholar]
  52. de Savigny D, Binka F, 2004. Monitoring future impact on malaria burden in sub-Saharan Africa. Am J Trop Med Hyg 71 (Suppl 2): 224–231. [Google Scholar]
  53. Bryce J, Rongou JB, Nguyen-Dinh P, Naimoli JF, Breman JG, 1994. Evaluation of national malaria control programmes in Africa. Bull World Health Org 72: 371–381. [Google Scholar]
  54. Monasch R, Reinisch A, Steketee R, 2004. Child coverage with mosquito nets and malaria treatment from population-based surveys in African countries: a baseline for monitoring progress in Roll Back Malaria. Am J Trop Med Hyg 71 (Suppl 2): 232–238. [Google Scholar]
  55. Ballou R, Arevalo-Herrera M, Carucci D, Richie TL, Corradin G, Diggs C, Druilhe P, Giersing BK, Saul A, Heppner DG, Kester KE, Lanar DE, Lyon J, Hill AVS, Pan W, Cohen JD, 2004. Update on the clinical development of candidate malaria vaccines. Am J Trop Med Hyg 71 (Suppl 2): 239–247. [Google Scholar]
  56. Hoffman SL, Goh LM, Luke TC, Schneider I, Le TP, Doolan DJ, Sacci J, de la Vega P, Dowler M, Paul C, Gordon DM, Stoute JA, Church LW, Sedegah M, Heppner DG, Ballou WR, Richie TL, 2002. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis 185: 1155–1164. [Google Scholar]
  57. Moree M, Ewart S, 2004. Policy challenges in malaria vaccine introduction. Am J Trop Med Hyg 71 (Suppl 2): 248–252. [Google Scholar]
  58. Ijumba J, Kitua A, 2004. Enhancing the application of effective malaria interventions in Africa through training. Am J Trop Med Hyg 71 (Suppl 2): 253–258. [Google Scholar]
  59. Royall J, Bennett M, van Schayk I, Alilio M, 2004. Tying up lions: Multilateral Initiative on Malaria Communications; the first chapter of a malaria research network in Africa. Am J Trop Med Hyg 71 (Suppl 2): 259–267. [Google Scholar]
  60. Alilio MS, Bygbjerg I, Breman JG, 2004. Are multilateral malaria research and control programs the most successful? Lessons from the past 100 years. Am J Trop Med Hyg 71 (Suppl 2): 268–278. [Google Scholar]
  61. Heddini A, Walgren M, Keusch G, Davies C, 2004. The Multilateral Initiative on Malaria: past, present and future. Am J Trop Med Hyg 71 (Suppl 2): 279–282. [Google Scholar]

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error